✦ LIBER ✦

Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma : A Phase II trial using a triplet combination

✍ Scribed by Swan-Swan Leong; Joseph Wee; Miah Hiang Tay; Chee Keong Toh; Say Beng Tan; Choon Hua Thng; Kian Fong Foo; Wan Teck Lim; Terence Tan; Eng Huat Tan

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 96 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20804

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Triplet combination of gemcitabine, pacl

Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma

✍ Swan Swan Leong; Joseph Wee; Sandeep Rajan; Chee Keong Toh; Wan Teck Lim; Siew W 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

Platinum-free combination chemotherapy i

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma : A Phase I/II trial of gemcitabine, paclitaxel, and methotrexate

✍ Primo N. Lara Jr; Frederick J. Meyers; Lisa Y. Law; Nancy A. Dawson; Joan Housto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND Platinum‐based regimens have improved response rates and survival in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract. However, the toxicities of platinum‐based chemotherapy are considerable. Regimens with reduced toxicity that are applicab

Paclitaxel, cisplatin, and gemcitabine c

Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma : A Phase II study

✍ Javier Rodriguez; Javier Cortes; Emiliano Calvo; Ignacio Azinovic; Oscar Fernand 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

Weekly paclitaxel and gemcitabine chemot

Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC) : A dose-optimizing phase II trial

✍ Vera Hirsh; Renaud Whittom; Linda Ofiara; Pierre Desjardins; Joseph Ayoub; Danie 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND The current dose‐optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non‐small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity. ## METHODS

Phase II trial of carboplatin, gemcitabi

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site

✍ Bryan J. Schneider; Basil El-Rayes; Jeffery H. Muler; Philip A. Philip; Gregory 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND. The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP). ## METHODS. Patients with CUP received carboplatin AUC 5 mg/mL a minute intraven

Phase II trial of carboplatin and paclit

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma : A Southwest Oncology Group study

✍ Ulka N. Vaishampayan; James R. Faulkner; Eric J. Small; Bruce G. Redman; Wayne L 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract ## BACKGROUND The purpose of the study was to assess the efficacy and toxicity of carboplatin and paclitaxel administered every 3 weeks in patients with advanced urothelial carcinoma, previously treated with cisplatin‐based therapy. ## METHODS Eligibility included metastatic or local